Interview
Leading Cancer Researcher: They’re Ignoring My Research
- A scientific paper currently under embargo is anticipated to become a lead article, providing the evidence base for a strategy to manage cancer without toxicity by extending patient survival.
- The speaker predicts that by 2026, cancer deaths in the United States will reach 626,000 (approximately 1,700 per day or 5,800 new diagnoses daily), with lung cancer remaining the leading cause of death and incidence steadily rising for breast, prostate, pancreatic, and melanoma cancers.
- Projections indicate that while standard therapies are standard, no major advances in managing glioblastoma have been made in 100 years, whereas metabolic therapies are reported to yield excellent results for pancreatic cancer and extend survival times for glioblastoma patients.
- Mitochondrial health is expected to be the primary determinant of human lifespan, with chronic damage from processed carbohydrates, inactivity, stress, and poor sleep driving the origin of cancer and chronic diseases, including type 2 diabetes and neuropsychiatric conditions.
- Acute stress on mitochondria can cause cell death via apoptosis or necrosis, whereas chronic impairment causes cells to revert to ancient fermentation pathways, leading to uncontrolled growth and requiring a supply of glucose and glutamine.
- Environmental factors such as "forever chemicals," microplastics, heavy metals like arsenic and cadmium, and acute stressors like cyanide are predicted to damage oxidative phosphorylation, with "forever chemicals" capable of crossing the placental wall to cause mitochondrial damage in children's organs.
- The speaker predicts that high-income countries like the United States, Australia, and New Zealand have the highest cancer rates compared to low-income nations, attributed to the combination of modern lifestyle factors causing chronic mitochondrial damage.
- Maintaining a Glucose Ketone Index (GKI) within the "green zone" (e.g., a GKI of 12.5) is expected to reduce cancer risk, while a GKI of 500 represents a "red zone" of high risk; nutritional ketosis is defined as ketone levels of 0.4 millimolar, distinct from pathological ketoacidosis (15–20 millimolar).
- Placing tumor cells in the "green zone" is predicted to deprive them of glucose, rendering them "incapacitated" or "indolent," though tumor growth may continue if glutamine remains available.
- Strategies to target cancer include combining ketogenic diets with drugs like metformin to block glucose and glutamine pathways, using nutritional ketosis to facilitate drug delivery allowing for lower chemotherapy doses, and utilizing hyperbaric oxygen therapy which is predicted to synergistically decrease tumor growth in animal models.
- A specific case is cited where a patient using metabolic therapy without radiation or chemotherapy is predicted to live for 10 years and become operable, while standard treatments like radiation and chemotherapy are warned to potentially push the body into a "Red Zone" that strengthens tumors.
- The field of oncology is expected to eventually accept cancer as a mitochondrial metabolic disorder, though currently, most mainstream oncologists advise against ketogenic diets due to fear of cachexia, and the somatic mutation theory is predicted to be rejected based on nuclear transfer experiments.
- Future developments include the use of apps to instantly calculate GKI via food photography, continuous glucose monitors to help patients maintain target zones, and the "press pulse therapeutic strategy" designed to target metastatic "glutamine-driven" hybrid cells.
- A commitment is made to continue research and education, supported by private foundations and philanthropy, with hopes that increased case reports will change the system and that public policy could focus on eliminating food deserts and providing free gym memberships.
- Risks include the inability of neurons to compensate for mitochondrial damage with fermentation leading to cell death in Parkinson's, the rarity of cancer in brain neurons compared to glial cells, and the potential for GLP-1 inhibitors to lower blood sugar without a certain effect on raising ketones.